doctype / docname

doctype: Sponsored Research Agreement

INTROGEN THERAPEUTICS INC. SPONSORED RESEARCH AGREEMENT (1996-09-03)

This Amendment No. 1 to Research Agreement ("AMENDMENT") is made and entered into as of July 20, 1994 by and between INTRON THERAPEUTICS, INC., a Delaware Corporation ("SPONSOR") and THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER ("CANCER CENTER"), a component institution of the University of Texas System ("SYSTEM").

INTROGEN THERAPEUTICS INC. SPONSORED RESEARCH AGREEMENT (1996-09-03)

INTROGEN THERAPEUTICS INC. SPONSORED RESEARCH AGREEMENT (1996-09-03)

This Amendment No. 1 to Research Agreement ("AMENDMENT") is made and entered into as of July 20, 1994 by and between INTRON THERAPEUTICS, INC., a Delaware Corporation ("SPONSOR") and THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER ("CANCER CENTER"), a component institution of the University of Texas System ("SYSTEM").

INTROGEN THERAPEUTICS INC. SPONSORED RESEARCH AGREEMENT (1996-09-03)

This Agreement, is made this 17th day of January, 1996 ("Effective Date"), by and between THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER (hereinafter referred to as "CANCER CENTER"), a component institution of The University of Texas System (hereinafter referred to as "SYSTEM"), located in Houston, Texas, and Introgen Therapeutics, Inc. (hereinafter referred to as "SPONSOR"), located in Austin, Texas.

INTROGEN THERAPEUTICS INC. SPONSORED RESEARCH AGREEMENT (1996-09-03)

THIS SPONSORED RESEARCH AGREEMENT (the "Agreement") is made as of March 29, 1996 ("Effective Date") by and between Sidney Kimmel Cancer Center ("SKCC") and Introgen Therapeutics, Inc., a Delaware corporation duly organized and existing under the laws of Delaware ("Sponsor").

TRIANGLE PHARMACEUTICALS INC. SPONSORED RESEARCH AGREEMENT (1996-09-11)

This Sponsored Research Agreement (the "Agreement"), made as of this 1st day of September, 1996, by and between The Regents of the University of California (the "Regents"), a California not-for-profit corporation, having its principal office at 300 Lakeside Drive, Oakland California 94612-3550, on behalf of the University of California, San Diego campus (the "University") and Triangle Pharmaceuticals, Inc. (the "Sponsor"), a Delaware for-profit corporation, having its principal office at 4 University Place, 4611 University Drive, Durham, North Carolina, 27707.

COMPUMED INC. SPONSORED RESEARCH AGREEMENT (1996-12-19)

This Agreement, effective as of May 1, 1996 (the "Effective Date"), is between the University of Massachusetts ("Institution"), a public institution of higher education of the Commonwealth of Massachusetts, and CompuMed, Inc. ("Sponsor"), a Delaware corporation.

INGENEX INC. SPONSORED RESEARCH AGREEMENT (1996-10-03)

This cycle is repeated once more and the spleen colonies are harvested and analyzed for the presence of MDR mRNA and protein. This protocol can be used for the generation of genetically modified mice. However, several parameters need to be examined in order to optimize the transduction frequency and the stability of the retroviral transgenome in the recipient mice.

INTROGEN THERAPEUTICS INC. SPONSORED RESEARCH AGREEMENT (1996-10-28)

This Amendment No. 1 to Research Agreement ("AMENDMENT") is made and entered into as of July 20, 1994 by and between INTRON THERAPEUTICS, INC., a Delaware Corporation ("SPONSOR") and THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER ("CANCER CENTER"), a component institution of the University of Texas System ("SYSTEM").

INTROGEN THERAPEUTICS INC. SPONSORED RESEARCH AGREEMENT (1996-10-28)

THIS SPONSORED RESEARCH AGREEMENT (the "Agreement") is made as of March 29, 1996 ("Effective Date") by and between Sidney Kimmel Cancer Center ("SKCC") and Introgen Therapeutics, Inc., a Delaware corporation duly organized and existing under the laws of Delaware ("Sponsor").

Google Adsense

more